Charles L. Daley, MD
Professor of Medicine
Head, Division of Mycobacterial and Respiratory Diseases
National Jewish Health
Phone: 303-398-1667
Fax: 303-398-1780
E-mail: daleyc@njc.org
Address:Campus Box A004
National Jewish Health
1400 Jackson Street, Room J204
Denver, CO
Medical School
- University of Mississippi Medical School, MD, 1979-1983
- Residencies
- University of California, San Francisco, Internal Medicine, 1983-1986
- University of California, San Francisco, Chief Resident, 1986-1987
- Fellowships
- University of California, San Francisco, Pulmonary and Critical Care Medicine, 1988-1991
- Research Interests
- Mycobacterial (TB/nontuberculous) and Respiratory Infections, Infectious Diseases, Allergic Pulmonary Bronchial Aspergillosis, Bronchiectasis, Drug-resistant Tuberculosis, Fungal Lung Disease, Immune Deficiencies, Infectious Diseases (Chronic Respiratory Infections), Nontuberculous Mycobacterial Infections, Sinusitis, Tuberculosis, Respiratory Infections
- My research has focused on clinical and epidemiological studies of tuberculosis and nontuberculous mycobacterial infections. In particular, I am interested in the molecular epidemiology of these infections and how we can better elucidate issues relevant to the transmission and pathogenesis of these important diseases. I am also interested in studying new diagnostic tests and new drugs and treatment regimens.
- In addition to my research I am very committed to medical education and training individuals to do clinical and epidemiologic research. I hope to develop a training program in mycobacterial diseases here at National Jewish.
Recent Publications
- Marras TK, Gonzalez L, Daley CL. Predictors of mortality in HIV-infected patients with pulmonary Mycobacterium kansasii. Am J Respir Crit Care Med 2004;170:793-798.
- Jasmer RM, Seaman C, Gonzalez LC, Kawamura LM, Daley CL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004;170:561-566.
- Ziv E, Daley CL, Blower S. Potential public health impact of tuberculosis vacccines. Emerg Infect Dis 2004;10:1529-1535.
- Jasmer RM., Snyder DC, Saukkonen JJ, Blumberg H, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL, for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-Course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A Cost-Effectiveness analysis based on a multicenter clinical trial. CID 2004; 38: 363-9.
- Ong A, Creasman J, Hopewell PC, Gonzalez L, Wong M, Jasmer RM, Daley CL. A molecular epidemiologic assessment of extrapulmonary tuberculosis in San Francisco. CID 2004;38: 25-31.